After an extensive national search, President Taylor Randall announced Bob S. Carter, M.D., Ph.D., a neurosurgeon, as the university’s new senior vice president for health sciences and CEO of University...
The drug lenacapavir, developed by Gilead Sciences, provides protection for half a year instead of one day and has performed extremely well in clinical trials.
Synthetic organisms, mirror-reversed on the molecular level from natural life, could be a possibility within decades. They could interact with humans and the environment in unpredictable, potentially dangerous ways.
The therapy increases the amount of blood the heart can pump and dramatically improves survival, in what a paper describing the results calls “an unprecedented recovery of cardiac function.”
